Steven W. Schlerholt, Esqual Executive Director



## **Memorandum of Response**

**To:** Danielle Dillard, Regulatory Policy Advocate

Common Sense Initiative

**From:** Ali Simon, Public and Policy Affairs Liaison

State of Ohio Board of Pharmacy

**Date:** August 13, 2018

**Re:** CSI Review – Drug Distributors (OAC 4729:6-1-01, 4729:6-2-01, 4729:6-2-

02, 4729:6-2-03, 4729:6-2-04, 4729:6-2-05, 4729:6-2-06, 4729:6-3-04, 4729:6-3-05, 4729:6-3-06, 4729:6-3-07, 4729:6-3-08, 4729:6-4-01, 4729:6-5-01, 4729:6-5-02, 4729:6-6-01, 4729:6-7-01, 4729:6-8-01, 4729:6-8-02, 4729:6-10-01, 4729:6-10-02, 4729:6-11-01, 4729:6-11-02, 4729-9-07, 4729-9-08, 4729-9-12, 4729-9-13, 4729-9-16, 4729-9-18, 4729-9-19, 4729-9-24, 4729-9-27, 4729-9-28,

4729-9-29, 4729-9-30, and 4729-16-02)

Thank you for your review of the rule package received by the Board of Pharmacy on August 9, 2018.

Based on your approval of the package, the State of Ohio Board of Pharmacy will continue its rule filing process with the Joint Committee on Agency Rule Review (JCARR).